Eli Lilly signs up to $1.1bn deal for Metis TechBio's AI lipid nanoparticle platform

Eli Lilly has signed a partnership worth up to $1.1 billion with Metis TechBio of Hong Kong for access to Metis' AI platform for designing lipid nanoparticles, the carriers used to deliver genetic and other advanced medicines. Metis announced the deal on 19 October 2026¹.

The terms

Lilly pays an upfront sum Metis describes as "low double-digit millions of U.S. dollars". The rest of the headline value comes through milestone payments, and Metis is also eligible for royalties on any products that result¹. On those figures, the cash committed at signing is a small fraction of the $1.1 billion, and most of the value depends on programmes reaching later stages.

The work centres on AiLNP, Metis' platform for discovering and optimising ionisable lipids. Metis bills it as the "world's first and only de novo lipid generation algorithm" and says it draws on a large lipid library, end-to-end screening and a lipid language model. According to Metis, the system looks for particles that reach target tissue more efficiently, cutting the time from computer design to validation in living models¹.

Metis started as an MIT idea in 2017 and had raised $86 million in Series A funding by 2021, to support a clinical trial in delivering small-molecule and RNA therapeutics¹.

What it means for the market

The deal shows a large pharma buyer paying for AI in drug delivery as well as in target and molecule discovery. "Delivery remains a critical determinant of therapeutic success, particularly as the industry expands into increasingly sophisticated modalities," said Metis chief executive Chris Lai¹.

For Lilly, it extends a run of delivery deals this year. The company has signed with QurCan Therapeutics, which works on polymer-lipid nanoparticles that cross the blood-brain barrier, with Entos Pharmaceuticals, which uses proteolipid vehicles for neurological delivery, and with academic groups including the University of Texas at Austin on LNP stability and performance¹. It has also bought Verve Therapeutics and Engage Biologics, both of which brought technology for delivering genetic material¹.

On the AI side, Lilly has invested in supercomputing with Nvidia and in the AI discovery company Insilico Medicine¹. Fierce Biotech links this spending to the cash generated by Lilly's GLP-1 weight loss drugs¹.

For AI platform vendors and their investors, the structure is the familiar one in platform licensing: a modest upfront fee, with the large headline figure contingent on milestones. For other delivery specialists, Lilly's string of deals across nanoparticle, polymer and proteolipid approaches suggests the company is spreading its bets across several delivery technologies rather than relying on one. The deal also adds to the flow of licensing between Western pharma and Chinese biotech, a theme Fierce Biotech flags in its coverage¹.

Caveats

The terms disclosed are limited. The source does not give the milestone schedule, the royalty rates, the tissues or diseases the collaboration will target, or how many programmes it covers¹. The performance claims for AiLNP are Metis' own and are not backed by data in the report¹. The $1.1 billion is a maximum that depends on future milestones, while the confirmed payment is the upfront sum in the low double-digit millions of dollars¹.